Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The prolonged half-lives of new erythropoietin derivatives via peptide addition.

Lee DE, Son W, Ha BJ, Oh MS, Yoo OJ.

Biochem Biophys Res Commun. 2006 Jan 6;339(1):380-5. Epub 2005 Nov 14.

PMID:
16314154
2.

Glycosylation-modified erythropoietin with improved half-life and biological activity.

Su D, Zhao H, Xia H.

Int J Hematol. 2010 Mar;91(2):238-44. doi: 10.1007/s12185-010-0496-x. Epub 2010 Feb 5.

PMID:
20131103
3.
4.

An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties.

Sytkowski AJ, Lunn ED, Risinger MA, Davis KL.

J Biol Chem. 1999 Aug 27;274(35):24773-8.

5.

Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell.

Joung CH, Shin JY, Koo JK, Lim JJ, Wang JS, Lee SJ, Tan HK, Kim SL, Lim SM.

Protein Expr Purif. 2009 Dec;68(2):137-45. doi: 10.1016/j.pep.2009.07.003. Epub 2009 Jul 10.

PMID:
19595770
6.

Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo.

Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E.

Blood. 2001 Jun 15;97(12):3776-82.

8.

[Expression of rhEPO-L-Fc fusion protein and analysis of its bioactivity and pharmacokinetics].

Zhu Q, Huang Z, Huang Y, Qin Y.

Sheng Wu Gong Cheng Xue Bao. 2008 Nov;24(11):1874-9. Chinese.

PMID:
19256332
10.

3'-Half of the thrombopoietin cDNA confers higher expression of erythropoietin at the RNA level but not at the protein level.

Kim TW, Ji JW, Chang HG, Kim MO, Ryoo ZY, Park IK, Kim SJ.

Mol Cells. 2005 Apr 30;19(2):198-204.

11.

Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties.

Cointe D, Béliard R, Jorieux S, Leroy Y, Glacet A, Verbert A, Bourel D, Chirat F.

Glycobiology. 2000 May;10(5):511-9.

PMID:
10764840
12.

Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli.

Wang YJ, Liu YD, Chen J, Hao SJ, Hu T, Ma GH, Su ZG.

Int J Pharm. 2010 Feb 15;386(1-2):156-64. doi: 10.1016/j.ijpharm.2009.11.016. Epub 2009 Nov 20.

PMID:
19932158
13.

A potent erythropoietin-mimicking human antibody interacts through a novel binding site.

Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, Simmer RL, Lacy SE, Egan DA, Harlan JE, Lesniewski RR, Reilly EB.

Blood. 2007 Oct 1;110(7):2408-13. Epub 2007 Jul 9.

14.

[Eukaryotic expression, purification and analysis of the fusion protein of Epo-Tpo(C)].

Wang Z, Hou Y, Yang X.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2001 Mar;15(1):5-8. Chinese.

PMID:
12526292
15.

Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.

Savino C, Pedotti R, Baggi F, Ubiali F, Gallo B, Nava S, Bigini P, Barbera S, Fumagalli E, Mennini T, Vezzani A, Rizzi M, Coleman T, Cerami A, Brines M, Ghezzi P, Bianchi R.

J Neuroimmunol. 2006 Mar;172(1-2):27-37. Epub 2005 Dec 7.

PMID:
16337691
16.

PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin.

Wang YJ, Hao SJ, Liu YD, Hu T, Zhang GF, Zhang X, Qi QS, Ma GH, Su ZG.

J Control Release. 2010 Aug 3;145(3):306-13. doi: 10.1016/j.jconrel.2010.04.021. Epub 2010 Apr 26.

PMID:
20427020
17.

Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity.

Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK.

Chem Biol. 1997 Dec;4(12):939-50.

PMID:
9427659
18.

Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925-30. doi: 10.1073/pnas.0805594105. Epub 2008 Aug 1.

19.

Development and characterization of novel erythropoiesis stimulating protein (NESP).

Egrie JC, Browne JK.

Br J Cancer. 2001 Apr;84 Suppl 1:3-10. Review.

20.

A new strategy for metabolic stabilization of motilin using the C-terminal part of ghrelin.

Morozumi N, Sato S, Yoshida S, Yamaki A, Furuya M, Inomata N, Ohnuma N, Minamitake Y, Ohsuye K, Kangawa K.

Peptides. 2012 Feb;33(2):279-84. doi: 10.1016/j.peptides.2012.01.010. Epub 2012 Jan 23.

PMID:
22286034

Supplemental Content

Support Center